IL1B and COVID-19: Treatment of these mice with anakinra (which blocks both IL-1α and IL-1β signaling) or with antibodies selectively targeting IL-1α significantly attenuated COVID-19-like pulmonary immunopathology, potentially identifying IL-1α as a mediator of inflammation and tissue-specific injury (54, 56).